FDA expands furosemide injection approval for adults with CHF

FDA has expanded approval of furosemide injection (Furoscix) to include treatment of congestion due to fluid overload in adult patients with CHF, regardless of New York Heart Association (NYHA) functional class. Previously, the novel furosemide delivery system was only indicated for patients with NYHA class II and class III CHF. According to the manufacturer, no additional clinical trial was needed to expand the indication to include patients with NYHA functional class IV; evidence from current literature was used to support the use of Furoscix in these patients.